October 01, 2014 1:25 PM ET

Pharmaceuticals

Company Overview of MyoKardia, Inc.

Company Overview

MyoKardia, Inc. develops a pipeline of small molecule therapeutics that addresses clinical needs for patients with genetic heart diseases. The company was founded in 2012 and is based in South San Francisco, California.

400 East Jamie Court

Suite 102

South San Francisco, CA 94080

United States

Founded in 2012

Phone:

650-741-0900

Key Executives for MyoKardia, Inc.

Chief Executive Officer and Director
Co-Founder
Co-Founder
Age: 72
Compensation as of Fiscal Year 2014.

MyoKardia, Inc. Key Developments

Sanofi and MyoKardia, Inc. Announce Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease

Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia`s pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction. The collaboration, representing one of the research and development commitments to genetic forms of cardiomyopathy, encompasses three MyoKardia programs. Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM). The collaboration provides up to $200 million in equity investments, milestone payments and research and development services through 2018, of which $45 million has already been received in an upfront licensing fee and an initial equity investment. In addition, Sanofi and MyoKardia will equally share development costs on the HCM programs following initial demonstration of efficacy in patients, with Sanofi fully covering the development costs of the DCM program. The collaboration is an outgrowth of Sanofi`s Sunrise initiative, a strategic partnership model that seeks to invest in early stage opportunities that align with Sanofi`s expert development and commercialization abilities. The commitment of resources from Sanofi will accelerate and broaden MyoKardia`s basic disease research and will support the shared commitment of bringing desperately needed therapies to patients. Within the collaboration, MyoKardia will drive research and worldwide development activities through early human efficacy studies. Thereafter, MyoKardia will lead worldwide development and U.S. commercial activities for the two HCM programs, where it has retained product rights, and Sanofi will lead global development and commercial activities for DCM where it has obtained worldwide rights, and ex-U.S. regulatory and commercial activities to the two HCM programs where it has ex-U.S. commercialization rights. Sanofi also has the option to co-promote in the U.S. for potential expanded cardiovascular diseases outside of the genetically targeted indications for either of the HCM programs, with MyoKardia having the option to co-promote the DCM program in the U.S.

MyoKardia, Inc Appoints Mark L. Perry to Board of Directors

MyoKardia, Inc. announced the appointment of Mark L. Perry to its board of directors, joining Tassos Gianakakos, Charles Homcy, M.D., and Kevin Starr. Mr. Perry currently serves as chairman of the board of Pathway Therapeutics and director of Nvidia Corporation. Mr. Perry is also a member of the California State Bar Association and the Association of Bioscience Financial Officers, and serves on several nonprofit boards.

MyoKardia, Inc. Announces Management Changes

MyoKardia, Inc. announced the appointment of Tassos Gianakakos to chief executive officer. Mr. Gianakakos succeeds founding CEO Charles Homcy, M.D., who will remain on MyoKardia's board of directors. Mr. Gianakakos brings more than 17 years of broad-based biopharmaceutical expertise to MyoKardia. He joins the company from MAP Pharmaceuticals, where he was most recently senior vice president and chief business officer.

Similar Private Companies By Industry

Company Name Region
Neurolink Medical, Inc. United States
Lundbeck Inc. United States
Xel Pharmaceuticals, Inc. United States
Glenmark Generics Inc. United States
AGY Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 1, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MyoKardia, Inc., please visit www.myokardia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.